Mark Esser, PhD, was appointed the inaugural chief scientific officer and head of the upcoming Paul and Diane Manning Institute of Biotechnology at Charlottesville-based University of Virginia. In his ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Sutter Health has named Dr. Matthew Solomon as its first chief scientific officer, a new executive role designed to integrate scientific research into patient care across the Sacramento-based ...

Professor Cinzia Casiraghi has been appointed as Chief Scientific Officer (CSO) at the Graphene Engineering Innovation Centre ...

Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT ...

Prior to her new role at Zenas, she served as the Chief Operating Officer at Tabby Therapeutics and held various leadership positions at Jounce Therapeutics, TESARO, Rhythm Pharmaceuticals ...

Prior to joining Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, a privately held biotech company focused on B-cell engineering where she led all scientific initiatives and ...

is pleased to announce the appointment of Jay Hexamer as its new Chief Executive Officer (CEO), effective immediately. This leadership transition reflects Biolyst Scientific's continued focus on ...

SunHydrogen, Inc. (OTC: HYSR) is pleased to announce the promotion of Dr. Syed Mubeen to the position of Chief Technology Officer (CTO) and the appointment ...